CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
Clotild Smart Guidewire System (CSGS)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06112054
NCT06112054N/ACompleted

Impedance Sensor Evaluated in Peripheral Artery Disease for Tissue Detection

Sensome·interventional·Posted Nov 1, 2023·Updated Mar 10, 2026

In Brief

A clinical study evaluating Clotild Smart Guidewire System (CSGS) for Peripheral Vascular Disease. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The objective of the study is to evaluate the feasibility of the CSGS sensor to differentiate tissues involved in Peripheral Artery Disease (PAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedNov 1, 2023
Enrollment StartNov 29, 2023
Primary CompletionAug 14, 2024
Study CompletionAug 15, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 2.7 years ago

Interventions

Clotild Smart Guidewire System (CSGS)device

In the current study, a commercially available CE marked guidewire will be used to direct a catheter through blood vessels while the Clotild® Smart Guidewire (study device) will only be used to perform electrophysiological measurements (via its sensor) in the blood vessels during peripheral endovascular procedures. It is thus designed for use as an adjunct to conventional angiographic procedure. During the procedure, the physician acquired measurements at several locations within the lesion to target the various tissues of interest. The physician labeled the data according to tissue type, relying on the patient's symptoms and other available clinical information.